Mealey's (March 8, 2016, 1:11 PM EST) -- CHICAGO — The Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on March 7 reconsidered his prior preemption ruling and said plaintiffs may pursue their claims for fraud based on off-label promotion of the drugs (In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL Docket No. 2545, No. 14-1748, N.D. Ill., Eastern Div.)....